Aegerion price target raised to $30 from $25 at Leerink Leerink raised its price target for Aegerion after the FDA approved Juxtapid. The firm reiterates an Outperform rating on Aegerion, noting the company obtained the broadest possible label possible for Juxtapid.
Aegerion price target lowered to $46 from $66 at Leerink Leerink lowered its price target for Aegerion shares to $46 after its survey of 40 U.S. cardiologists implied a more bearish outlook for Juxtapid once PCSK9s emerge. The firm, however, believes new patient adds are well outpacing Juxtapid discontinuations in the near term. It keeps an Outperform rating on the stock.